Dynavax DVAX Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Dynavax DVAX

DVAX 10.26

-1.3%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: fred hayes	2/25/2013 7:34:26 PM
	Read Replies (1) of 184

Finally got around to the conference call. My conclusions from listening. - meeting with fda within 6 weeks or so and expect guidance to allow refile for more focused population, maybe chronic kidney disease and over 40 years of age. - over 40 years of age is about half the market; ckd around 25 percent (don't add these together). - Still under review in Europe and hopeful for approval. - If everything goes as expected with fda meeting, should not take long to refile. Already have the data and no new clinical trial will be required. - finished year with $125 million. If you're thinking of getting in here you should listen for yourself, sometimes I mishear things...(:>)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next